دورية أكاديمية
Prevalence and clinical implications of germline pathogenic variants in cancer predisposing genes in young patients across sarcoma subtypes.
| العنوان: | Prevalence and clinical implications of germline pathogenic variants in cancer predisposing genes in young patients across sarcoma subtypes. |
|---|---|
| المؤلفون: | Carvalho NA; Clinical and Functional Genomics Group, ACCamargo Cancer Center, Sao Paulo, São Paulo, Brazil., Santiago KM; Clinical and Functional Genomics Group, ACCamargo Cancer Center, Sao Paulo, São Paulo, Brazil., Maia JML; Clinical Oncology Department, ACCamargo Cancer Center, Sao Paulo, Brazil., Costa FD; Department of Anatomic Pathology, ACCamargo Cancer Center, Sao Paulo, Brazil., Formiga MN; Oncogenetics Department, ACCamargo Cancer Center, Sao Paulo, Brazil., Soares DCQ; Oncogenetics Department, ACCamargo Cancer Center, Sao Paulo, Brazil., Paixão D; Oncogenetics Department, ACCamargo Cancer Center, Sao Paulo, Brazil., Mello CAL; Clinical Oncology Department, ACCamargo Cancer Center, Sao Paulo, Brazil., Costa CMLD; Pediatric Oncology Department, ACCamargo Cancer Center, Sao Paulo, Brazil., Rocha JCCD; Oncogenetics Department, ACCamargo Cancer Center, Sao Paulo, Brazil., Rivera B; Molecular Mechanisms and Experimental Therapy in Oncology Program, IDIBELL, Barcelona, Spain.; Gerald Bronfman Department of Oncology, McGill University, Montreal, Québec, Canada., Carraro DM; Clinical and Functional Genomics Group, ACCamargo Cancer Center, Sao Paulo, São Paulo, Brazil.; National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation, Sao Paulo, Brazil., Torrezan GT; Clinical and Functional Genomics Group, ACCamargo Cancer Center, Sao Paulo, São Paulo, Brazil giovana.torrezan@accamargo.org.br.; National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation, Sao Paulo, Brazil. |
| المصدر: | Journal of medical genetics [J Med Genet] 2023 Dec 21; Vol. 61 (1), pp. 61-68. Date of Electronic Publication: 2023 Dec 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: British Medical Association Country of Publication: England NLM ID: 2985087R Publication Model: Electronic Cited Medium: Internet ISSN: 1468-6244 (Electronic) Linking ISSN: 00222593 NLM ISO Abbreviation: J Med Genet Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : British Medical Association |
| مواضيع طبية MeSH: | Genetic Predisposition to Disease* , Sarcoma*/epidemiology , Sarcoma*/genetics, Child ; Young Adult ; Adolescent ; Humans ; Prevalence ; Germ-Line Mutation/genetics ; Germ Cells ; Xeroderma Pigmentosum Group D Protein/genetics ; DNA Helicases/genetics |
| مستخلص: | Background: Sarcomas are a rare and diverse group of cancers occurring mainly in young individuals for which an underlying germline genetic cause remains unclear in most cases. Methods: Germline DNA from 177 children, adolescents and young adults with soft tissue or bone sarcomas was tested using multigene panels with 113 or 126 cancer predisposing genes (CPGs) to describe the prevalence of germline pathogenic/likely pathogenic variants (GPVs). Subsequent testing of a subset of tumours for loss of heterozygosity (LOH) evaluation was performed to investigate the clinical and molecular significance of these variants. Results: GPVs were detected in 21.5% (38/177) of the patients (15.8% in children and 21.6% in adolescents and young adults), with dominant CPGs being altered in 15.2% overall. These variants were found in genes previously associated with the risk of developing sarcomas ( TP53 , RB1 , NF1 , EXT1/2 ) but also in genes where that risk is still emerging/limited ( ERCC2 , TSC2 and BRCA2 ) or unknown ( PALB2 , RAD50 , FANCM and others). The detection rates of GPVs varied from 0% to 33% across sarcoma subtypes and GPV carriers were more likely to present more than one primary tumour than non-carriers (21.1%×6.5%; p=0.012). Loss of the wild-type allele was detected in 48% of tumours from GPV carriers, mostly in genes definitively associated with sarcoma risk. Conclusion: Our findings reveal that a high proportion of young patients with sarcomas presented a GPV in a CPG, underscoring the urgency of establishing appropriate genetic screening strategies for these individuals and their families. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| References: | PLoS One. 2020 Jan 24;15(1):e0227260. (PMID: 31978118) Eur J Hum Genet. 2017 Nov;25(11):1278-1281. (PMID: 28853721) J Natl Cancer Inst. 2007 Jan 3;99(1):24-31. (PMID: 17202110) J Pathol. 2015 Jun;236(2):210-8. (PMID: 25644707) Lancet Oncol. 2016 Sep;17(9):1261-71. (PMID: 27498913) Nat Genet. 2019 Nov;51(11):1560-1565. (PMID: 31676867) Clin Lung Cancer. 2020 Mar;21(2):e37-e44. (PMID: 31889631) J Radiol Prot. 2009 Jun;29(2A):A61-79. (PMID: 19454806) Ann Oncol. 2021 Nov;32(11):1348-1365. (PMID: 34303806) Eur J Cell Biol. 2014 Jan-Feb;93(1-2):71-5. (PMID: 24290354) Sci Rep. 2020 Oct 13;10(1):17051. (PMID: 33051548) Adv Anat Pathol. 2021 Jan;28(1):44-58. (PMID: 32960834) Cancer. 2012 Mar 1;118(5):1387-96. (PMID: 21837677) Cancer Res. 2017 Nov 1;77(21):e31-e34. (PMID: 29092934) J Surg Oncol. 2015 Apr;111(5):490-5. (PMID: 25335907) Transl Androl Urol. 2020 Oct;9(5):2430-2440. (PMID: 33209717) Cancer. 2005 Jun 1;103(11):2391-6. (PMID: 15852362) Front Oncol. 2020 Oct 02;10:571330. (PMID: 33134171) World Neurosurg. 2018 Jan;109:362-364. (PMID: 29061454) PLoS One. 2014 Apr 11;9(4):e93455. (PMID: 24728235) Cancers (Basel). 2020 Jul 09;12(7):. (PMID: 32659967) Oncologist. 2016 Aug;21(8):1002-13. (PMID: 27401891) J Clin Oncol. 2013 Jul 10;31(20):2619-26. (PMID: 23733769) Carcinogenesis. 2017 Oct 26;38(11):1112-1118. (PMID: 28968711) Orphanet J Rare Dis. 2013 Apr 05;8:54. (PMID: 23561487) JAMA Oncol. 2016 Mar;2(3):373-9. (PMID: 26659639) Genet Med. 2022 Aug;24(8):1732-1742. (PMID: 35507016) Am J Hum Genet. 2022 Jun 2;109(6):1026-1037. (PMID: 35512711) JAMA Oncol. 2017 Oct 01;3(10):1400-1402. (PMID: 28114597) Sci Rep. 2017 Sep 6;7(1):10660. (PMID: 28878254) Nat Commun. 2022 Mar 30;13(1):1831. (PMID: 35354829) Pediatr Radiol. 2009 Feb;39 Suppl 1:S27-31. (PMID: 19083227) Genet Med. 2015 May;17(5):405-24. (PMID: 25741868) Cold Spring Harb Perspect Med. 2016 Dec 1;6(12):. (PMID: 27663983) JCO Precis Oncol. 2021 Jan 11;5:. (PMID: 34095712) Nature. 2014 Jan 16;505(7483):302-8. (PMID: 24429628) Cell. 2018 Apr 5;173(2):355-370.e14. (PMID: 29625052) NPJ Breast Cancer. 2022 Jan 17;8(1):9. (PMID: 35039532) JAMA Oncol. 2020 May 1;6(5):724-734. (PMID: 32191290) Eur J Hum Genet. 2022 Mar;30(3):265-270. (PMID: 34983940) Nature. 2011 Oct 19;480(7375):94-8. (PMID: 22012259) Hered Cancer Clin Pract. 2021 Jul 21;19(1):32. (PMID: 34289891) Lancet Oncol. 2016 Sep;17(9):1179-81. (PMID: 27498912) Adv Anat Pathol. 2018 Jul;25(4):217-222. (PMID: 29668499) Am J Pathol. 2010 Oct;177(4):1946-57. (PMID: 20813973) Sci Adv. 2020 Jun 24;6(26):eaba3231. (PMID: 32637605) |
| فهرسة مساهمة: | Keywords: genetic predisposition to disease; genetic variation; neoplasms |
| المشرفين على المادة: | EC 5.99.- (ERCC2 protein, human) EC 3.6.4.12 (Xeroderma Pigmentosum Group D Protein) EC 3.6.1.- (FANCM protein, human) EC 3.6.4.- (DNA Helicases) |
| تواريخ الأحداث: | Date Created: 20230803 Date Completed: 20231225 Latest Revision: 20240125 |
| رمز التحديث: | 20240125 |
| مُعرف محوري في PubMed: | PMC10803955 |
| DOI: | 10.1136/jmg-2023-109269 |
| PMID: | 37536918 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!